Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation

Allen LM, Creaven PJ (1975) Pharmacokinetics of ifosfamide. Clin Pharmacol Ther 17:492 Brade W, Seeber S, Herdrich K (1986) Comparative activity of ifosfamide and cyclophosphamide. Cancer Chemother Pharmacol 18 (Suppl 2): S1-S9 Breimer DD (1983) Interindividual variations in drug disposition. Clinical implications and methods of investigation. Clin Pharmacokinet 8:371 Brock N (1983) Oxazaphosphorine cytostatics: structure activity relationships, selectivity and metabolism, regional detoxification. In: Structure-activity Relationships of Anti-tumour Agents, edited by D.N. Reinhoudt, T.A. Connors, H.M. Pinedo and K.W. van de Poll (Boston: Martinus Nijhoff Publishers), 239 Clark DWJ (1985) Genetically determined variability in acetylation and oxidation. Therapeutic implications. Drugs 29:342 Colvin M (1982) The comparative pharmacology of cyclophosphamide and ifosfamide. Semin Oncol 9:2 Connors TA, Cox PJ, Farmer PR, Foster AB, Jarman M (1974) Some studies of the active intermediates formed in the microsomal metabolites of cyclophosphamide and ifosfamide. Biochem Pharmacol 23:115 Eichelbaum M (1982) Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet 7:1 Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17:102 Friedman OM, Boger E (1961) Colorimetric estimation of nitrogen mustards in aqueous media. Hydrolytic behaviour of bis (beta-chloroethyl) amine, nor HN2. Anal Chem 33:906 Hill DL, Laster WF Jr, Kirk MC, El Dareer S, Struck RF (1973) Metabolism of ifosfamide and production of a toxic ifosfamide metabolite. Cancer Res 33:1016 Juma FJ, Rogers HJ, Trounce JR (1979) Pharmacokinetics of cyclophosphamide and alkylating activity in urine after intravenous and oral administration. Br J Clin Pharmacol 8:209 Kalow W (1987) Genetic variation in the human hepatic cytochrome P-450 system. Eur J Clin Pharmacol 31:633 Lennard MS, Silas JH, Tucker GT (1977) Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogenselective detection. J Chromatogr 133:161 Lu AYH, West SB (1980) Multiplicity of mammalian microsomal cytochrome P-450. Pharmacol Rev 31:277 Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet ii:584 Meyer UA, Gut J, Kronbach T, Skoda R, Meier UT, Dayer P (1986) The molecular mechanisms of common polymorphisms of drug oxidation—evidence for functional changes in cytochrome P-450 isoenzymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica 16:449 Norpoth K (1976) Studies on the metabolism of ifosphosphamide (NSC-109724) in man. Cancer Treat Rep 60:437 Park BK (1982) Assessment of the drug metabolism capacity of the liver. Br J Clin Pharmacol 14:631 Siegel S (1956) Non parametric statistics for the behavioural sciences. McGraw-Hill Inc., New York Sloan TP, Lancaster R, Shah RR, Idle JR, Smith RL (1983) Genetically determined oxidation capacity and the disposition of debrisoquine. Br J Clin Pharmacol 15:443 Talha MRZ, Rogers HJ (1984) Rapid gas chromatographic determination of ifosfamide in biological fluids. J Chromatogr 311:194 Van Dyk JJ, Falkson HC, Van der Merwe AM, Falkson G (1972) Unexpected toxicity in patients with ifosphamide. Cancer Res 32:921 Vesell ES (1977) Genetic and environmental factors affecting drug disposition in man. Clin Pharmacol Ther 22:659